801 related articles for article (PubMed ID: 12847155)
1. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.
Orgogozo JM; Gilman S; Dartigues JF; Laurent B; Puel M; Kirby LC; Jouanny P; Dubois B; Eisner L; Flitman S; Michel BF; Boada M; Frank A; Hock C
Neurology; 2003 Jul; 61(1):46-54. PubMed ID: 12847155
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.
Gilman S; Koller M; Black RS; Jenkins L; Griffith SG; Fox NC; Eisner L; Kirby L; Rovira MB; Forette F; Orgogozo JM;
Neurology; 2005 May; 64(9):1553-62. PubMed ID: 15883316
[TBL] [Abstract][Full Text] [Related]
3. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
4. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.
Fox NC; Black RS; Gilman S; Rossor MN; Griffith SG; Jenkins L; Koller M;
Neurology; 2005 May; 64(9):1563-72. PubMed ID: 15883317
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD.
Bayer AJ; Bullock R; Jones RW; Wilkinson D; Paterson KR; Jenkins L; Millais SB; Donoghue S
Neurology; 2005 Jan; 64(1):94-101. PubMed ID: 15642910
[TBL] [Abstract][Full Text] [Related]
6. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.
Ferrer I; Boada Rovira M; Sánchez Guerra ML; Rey MJ; Costa-Jussá F
Brain Pathol; 2004 Jan; 14(1):11-20. PubMed ID: 14997933
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and immunogenicity of an active anti-Aβ
Lacosta AM; Pascual-Lucas M; Pesini P; Casabona D; Pérez-Grijalba V; Marcos-Campos I; Sarasa L; Canudas J; Badi H; Monleón I; San-José I; Munuera J; Rodríguez-Gómez O; Abdelnour C; Lafuente A; Buendía M; Boada M; Tárraga L; Ruiz A; Sarasa M
Alzheimers Res Ther; 2018 Jan; 10(1):12. PubMed ID: 29378651
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
9. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.
Agadjanyan MG; Ghochikyan A; Petrushina I; Vasilevko V; Movsesyan N; Mkrtichyan M; Saing T; Cribbs DH
J Immunol; 2005 Feb; 174(3):1580-6. PubMed ID: 15661919
[TBL] [Abstract][Full Text] [Related]
10. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
[TBL] [Abstract][Full Text] [Related]
11. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
Lemere CA
Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
[TBL] [Abstract][Full Text] [Related]
12. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.
Vellas B; Black R; Thal LJ; Fox NC; Daniels M; McLennan G; Tompkins C; Leibman C; Pomfret M; Grundman M;
Curr Alzheimer Res; 2009 Apr; 6(2):144-51. PubMed ID: 19355849
[TBL] [Abstract][Full Text] [Related]
14. Novel Abeta immunogens: is shorter better?
Lemere CA; Maier M; Peng Y; Jiang L; Seabrook TJ
Curr Alzheimer Res; 2007 Sep; 4(4):427-36. PubMed ID: 17908047
[TBL] [Abstract][Full Text] [Related]
15. Downregulated apoptosis and autophagy after anti-Aβ immunotherapy in Alzheimer's disease.
Paquet C; Nicoll JA; Love S; Mouton-Liger F; Holmes C; Hugon J; Boche D
Brain Pathol; 2018 Sep; 28(5):603-610. PubMed ID: 29027727
[TBL] [Abstract][Full Text] [Related]
16. Microglial alterations in human Alzheimer's disease following Aβ42 immunization.
Zotova E; Holmes C; Johnston D; Neal JW; Nicoll JA; Boche D
Neuropathol Appl Neurobiol; 2011 Aug; 37(5):513-24. PubMed ID: 21166690
[TBL] [Abstract][Full Text] [Related]
17. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
Cribbs DH
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
[TBL] [Abstract][Full Text] [Related]
18. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
Pride M; Seubert P; Grundman M; Hagen M; Eldridge J; Black RS
Neurodegener Dis; 2008; 5(3-4):194-6. PubMed ID: 18322388
[TBL] [Abstract][Full Text] [Related]
19. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1.
Buckwalter MS; Coleman BS; Buttini M; Barbour R; Schenk D; Games D; Seubert P; Wyss-Coray T
J Neurosci; 2006 Nov; 26(44):11437-41. PubMed ID: 17079673
[TBL] [Abstract][Full Text] [Related]
20. Refining an Alzheimer's vaccine to avoid an inflammatory response.
Brown ME; DaSilva KA; McLaurin J
Expert Opin Biol Ther; 2005 Jun; 5(6):809-16. PubMed ID: 15952911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
